Orphelia Pharma SA

The European Medicines Agency is due to decide this week whether to recommend pan-EU marketing authorization for several products, including two treatments that are yet to be approved anywhere in the

The European Medicines Agency has recommended that pan-EU marketing authorization should be granted to eight new drugs, including Gohibic (vilobelimab) and Augtyro (repotrectinib), from InflaRx and Br

The European Medicines Agency said on 15 November that pan-EU marketing authorizations should be refused for Kizfizo (temozolomide) and Cinainu (allium/citrus/paullinia/cacao), which are two treatment

The developers of Coacillium, vilobelimab, avacincaptad pegol and temozolomide were this week due to provide the European Medicines Agency with oral explanations as to why their respective drugs, whic